227 related articles for article (PubMed ID: 29803985)
1. Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.
Bohula EA; Scirica BM; Fanola C; Inzucchi SE; Keech A; McGuire DK; Smith SR; Abrahamsen T; Francis BH; Miao W; Perdomo CA; Satlin A; Wiviott SD; Sabatine MS
Am Heart J; 2018 Aug; 202():39-48. PubMed ID: 29803985
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.
Bohula EA; Wiviott SD; McGuire DK; Inzucchi SE; Kuder J; Im K; Fanola CL; Qamar A; Brown C; Budaj A; Garcia-Castillo A; Gupta M; Leiter LA; Weissman NJ; White HD; Patel T; Francis B; Miao W; Perdomo C; Dhadda S; Bonaca MP; Ruff CT; Keech AC; Smith SR; Sabatine MS; Scirica BM;
N Engl J Med; 2018 Sep; 379(12):1107-1117. PubMed ID: 30145941
[TBL] [Abstract][Full Text] [Related]
3. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM;
J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446
[TBL] [Abstract][Full Text] [Related]
4. Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial.
Scirica BM; Bohula EA; Dwyer JP; Qamar A; Inzucchi SE; McGuire DK; Keech AC; Smith SR; Murphy SA; Im K; Leiter LA; Gupta M; Patel T; Miao W; Perdomo C; Bonaca MP; Ruff CT; Sabatine MS; Wiviott SD;
Circulation; 2019 Jan; 139(3):366-375. PubMed ID: 30586726
[TBL] [Abstract][Full Text] [Related]
5. Lorcaserin: an investigational serotonin 2C agonist for weight loss.
Hurren KM; Berlie HD
Am J Health Syst Pharm; 2011 Nov; 68(21):2029-37. PubMed ID: 22011982
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability review of lorcaserin in clinical trials.
Greenway FL; Shanahan W; Fain R; Ma T; Rubino D
Clin Obes; 2016 Oct; 6(5):285-95. PubMed ID: 27627785
[TBL] [Abstract][Full Text] [Related]
7. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.
Bohula EA; Scirica BM; Inzucchi SE; McGuire DK; Keech AC; Smith SR; Kanevsky E; Murphy SA; Leiter LA; Dwyer JP; Corbalan R; Hamm C; Kaplan L; Nicolau JC; Ophuis TO; Ray KK; Ruda M; Spinar J; Patel T; Miao W; Perdomo C; Francis B; Dhadda S; Bonaca MP; Ruff CT; Sabatine MS; Wiviott SD;
Lancet; 2018 Nov; 392(10161):2269-2279. PubMed ID: 30293771
[TBL] [Abstract][Full Text] [Related]
8. Lorcaserin Hcl for the treatment of obesity.
Shukla AP; Kumar RB; Aronne LJ
Expert Opin Pharmacother; 2015; 16(16):2531-8. PubMed ID: 26472579
[TBL] [Abstract][Full Text] [Related]
9. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
Nissen SE; Wolski KE; Prcela L; Wadden T; Buse JB; Bakris G; Perez A; Smith SR
JAMA; 2016 Mar; 315(10):990-1004. PubMed ID: 26954408
[TBL] [Abstract][Full Text] [Related]
10. Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith SR; Weissman NJ; Anderson CM; Sanchez M; Chuang E; Stubbe S; Bays H; Shanahan WR;
N Engl J Med; 2010 Jul; 363(3):245-56. PubMed ID: 20647200
[TBL] [Abstract][Full Text] [Related]
11. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.
Nigro SC; Luon D; Baker WL
Curr Med Res Opin; 2013 Jul; 29(7):839-48. PubMed ID: 23574263
[TBL] [Abstract][Full Text] [Related]
12. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials.
Weissman NJ; Sanchez M; Koch GG; Smith SR; Shanahan WR; Anderson CM
Circ Cardiovasc Imaging; 2013 Jul; 6(4):560-7. PubMed ID: 23661689
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials.
Aronne L; Shanahan W; Fain R; Glicklich A; Soliman W; Li Y; Smith S
Postgrad Med; 2014 Oct; 126(6):7-18. PubMed ID: 25414931
[TBL] [Abstract][Full Text] [Related]
14. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis.
Nguyen CT; Zhou S; Shanahan W; Fain R
Clin Ther; 2016 Jun; 38(6):1498-1509. PubMed ID: 27206567
[TBL] [Abstract][Full Text] [Related]
15. The safety and efficacy of lorcaserin in the management of obesity.
Hess R; Cross LB
Postgrad Med; 2013 Nov; 125(6):62-72. PubMed ID: 24200762
[TBL] [Abstract][Full Text] [Related]
16. Lorcaserin. In obesity: unacceptable risks.
Prescrire Int; 2014 May; 23(149):117-20. PubMed ID: 24926508
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of lorcaserin in obesity: a systematic review and meta-analysis of randomized controlled trials.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):183-190. PubMed ID: 31815555
[No Abstract] [Full Text] [Related]
18. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.
O'Neil PM; Smith SR; Weissman NJ; Fidler MC; Sanchez M; Zhang J; Raether B; Anderson CM; Shanahan WR
Obesity (Silver Spring); 2012 Jul; 20(7):1426-36. PubMed ID: 22421927
[TBL] [Abstract][Full Text] [Related]
19. Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six-month, randomized, placebo-controlled, double-blind clinical trial.
Tuccinardi D; Farr OM; Upadhyay J; Oussaada SM; Mathew H; Paschou SA; Perakakis N; Koniaris A; Kelesidis T; Mantzoros CS
Diabetes Obes Metab; 2019 Jun; 21(6):1487-1492. PubMed ID: 30724455
[TBL] [Abstract][Full Text] [Related]
20. Effects of lorcaserin on cardiometabolic risk factors in overweight and obese patients: A systematic review and meta-analysis.
Kuo HH; Wang KT; Lee YH; Lin PL; Liu ME; Lin CY; Liu LY
J Clin Pharm Ther; 2020 Feb; 45(1):35-44. PubMed ID: 31544267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
